HELP
$4.86
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Intraday
Recent News
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data
Cybin (HELP) is back in focus after Helus Pharma reported Phase 2 topline data for HLP004 in generalized anxiety disorder, showing clinically meaningful symptom reductions and durable remission in patients who had remained symptomatic on standard care. See our latest analysis for Cybin. Despite the upbeat Phase 2 readout and recent conference appearances, momentum in Cybin’s share price has been weak. The 7 day share price return is 28.57% and the 1 year total shareholder return is 27.98%,...
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Cresco Labs Reported Q4 Revenue Growth Momentum as Margins Improved Tilray Expanded Beverage Push With $60 Million BrewDog Asset Acquisition Key Takeaways; Psychedelic Sector Helus Pharma Reported Promising Phase 2 Results for Anxiety Treatment GH Research Highlighted Strong 2025 Progress as It Prepares to Advance Its Depression Therapy Program AtaiBeckley is […]
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact?
In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized anxiety disorder who remained symptomatic on standard antidepressant therapy, showing clinically meaningful anxiety reductions, durable remission rates over six months, and a favorable tolerability profile without drug-related serious adverse events. These data highlight HLP004’s potential to fill a...
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise
See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.